0001453687-24-000063.txt : 20240410
0001453687-24-000063.hdr.sgml : 20240410
20240410214019
ACCESSION NUMBER: 0001453687-24-000063
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240408
FILED AS OF DATE: 20240410
DATE AS OF CHANGE: 20240410
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SPRINGER TIMOTHY A
CENTRAL INDEX KEY: 0001055624
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37798
FILM NUMBER: 24836988
MAIL ADDRESS:
STREET 1: 36 WOODMAN ROAD
CITY: CHESTNUT HILL
STATE: MA
ZIP: 02467
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cartesian Therapeutics, Inc.
CENTRAL INDEX KEY: 0001453687
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-923-1400
MAIL ADDRESS:
STREET 1: 65 GROVE STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: SELECTA BIOSCIENCES INC
DATE OF NAME CHANGE: 20090109
4
1
wk-form4_1712799609.xml
FORM 4
X0508
4
2024-04-08
0
0001453687
Cartesian Therapeutics, Inc.
RNAC
0001055624
SPRINGER TIMOTHY A
36 WOODMAN ROAD
CHESTNUT HILL
MA
02467
1
0
1
0
0
Series A Non-Voting Convertible Preferred Stock
2024-04-08
4
M
0
123925.407
D
0
D
Common Stock
2024-04-08
4
M
0
4130846
A
4379899
D
Series A Non-Voting Convertible Preferred Stock
2024-04-08
4
M
0
24785.081
D
0
I
See Footnote
Common Stock
2024-04-08
4
M
0
826169
A
1927630
I
See Footnote
Common Stock
3493
I
By wife
Stock Option (Right to Buy)
19.656
2034-01-01
Common Stock
7600
7600
D
Warrant (Right to Buy)
46.50
2022-04-11
2027-04-11
Common Stock
167040
167040
I
See Footnote
On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the "Reverse Stock Split") of the issuer's common stock ("Common Stock") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock.
On April 4, 2024, the issuer effected the "Reverse Stock Split". The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.
Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
This award will vest in 36 equal monthly installments, so that it shall be fully vested on the third anniversary of the date of grant.
/s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer
2024-04-10